Last reviewed · How we verify
Salmeterol/ fluticasone propionate
Salmeterol is a long-acting beta-2 agonist that relaxes airway smooth muscle, while fluticasone propionate is a corticosteroid that reduces airway inflammation.
Salmeterol is a long-acting beta-2 agonist that relaxes airway smooth muscle, while fluticasone propionate is a corticosteroid that reduces airway inflammation. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | Salmeterol/ fluticasone propionate |
|---|---|
| Also known as | SERETIDE |
| Sponsor | GlaxoSmithKline |
| Drug class | Long-acting beta-2 agonist / inhaled corticosteroid combination |
| Target | Beta-2 adrenergic receptor; glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Salmeterol binds to beta-2 adrenergic receptors on bronchial smooth muscle, causing bronchodilation and lasting 12 hours. Fluticasone propionate binds to glucocorticoid receptors in the airway, suppressing inflammatory cell recruitment and cytokine production. Together, they provide both sustained bronchodilation and anti-inflammatory effects for asthma and COPD control.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Nervousness
- Palpitations
- Oral candidiasis
- Dysphonia
Key clinical trials
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (PHASE2)
- Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation (NA)
- A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. (PHASE3)
- Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma (PHASE4)
- Advair HFA in Healthy and HAPE Predisposed Subjects (PHASE1, PHASE2)
- Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation (PHASE3)
- Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion (NA)
- Asthma Research in Children and Adolescents
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Salmeterol/ fluticasone propionate CI brief — competitive landscape report
- Salmeterol/ fluticasone propionate updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI